Differential diagnosis of vitamin D–related hypercalcemia using serum vitamin D metabolite profiling

ABSTRACT Genetic causes of vitamin D–related hypercalcemia are known to involve mutation of 25‐hydroxyvitamin D‐24‐hydroxylase CYP24A1 or the sodium phosphate co‐transporter SLC34A1, which result in excessive 1,25‐(OH)2D hormonal action. However, at least 20% of idiopathic hypercalcemia (IH) cases r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of bone and mineral research 2021-07, Vol.36 (7), p.1340-1350
Hauptverfasser: Kaufmann, Martin, Schlingmann, Karl‐Peter, Berezin, Linor, Molin, Arnaud, Sheftel, Jesse, Vig, Melanie, Gallagher, John C., Nagata, Akiko, Masoud, Shadi Sedghi, Sakamoto, Ryota, Nagasawa, Kazuo, Uesugi, Motonari, Kottler, Marie Laure, Konrad, Martin, Jones, Glenville
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1350
container_issue 7
container_start_page 1340
container_title Journal of bone and mineral research
container_volume 36
creator Kaufmann, Martin
Schlingmann, Karl‐Peter
Berezin, Linor
Molin, Arnaud
Sheftel, Jesse
Vig, Melanie
Gallagher, John C.
Nagata, Akiko
Masoud, Shadi Sedghi
Sakamoto, Ryota
Nagasawa, Kazuo
Uesugi, Motonari
Kottler, Marie Laure
Konrad, Martin
Jones, Glenville
description ABSTRACT Genetic causes of vitamin D–related hypercalcemia are known to involve mutation of 25‐hydroxyvitamin D‐24‐hydroxylase CYP24A1 or the sodium phosphate co‐transporter SLC34A1, which result in excessive 1,25‐(OH)2D hormonal action. However, at least 20% of idiopathic hypercalcemia (IH) cases remain unresolved. In this case‐control study, we used precision vitamin D metabolite profiling based on liquid chromatography–tandem mass spectrometry (LC‐MS/MS) of an expanded range of vitamin D metabolites to screen German and French cohorts of hypercalcemia patients, to identify patients with altered vitamin D metabolism where involvement of CYP24A1 or SLC34A1 mutation had been ruled out and who possessed normal 25‐OH‐D3:24,25‐(OH)2D3 ratios. Profiles were compared to those of hypercalcemia patients with hypervitaminosis D, Williams‐Beuren syndrome (WBS), CYP24A1 mutation, and normal subjects with a range of 25‐OH‐D levels. We observed that certain IH and WBS patients exhibited a unique profile comprising eightfold to 10‐fold higher serum 23,25,26‐(OH)3D3 and 25‐OH‐D3‐26,23‐lactone than normals, as well as very low serum 1,25‐(OH)2D3 (2–5 pg/ml) and elevated 1,24,25‐(OH)3D3, which we interpret implies hypersensitive expression of vitamin D–dependent genes, including CYP24A1, as a general underlying mechanism of hypercalcemia in these patients. Because serum 25‐OH‐D3 and 24,25‐(OH)2D3 remained normal, we excluded the possibility that the aberrant profile was caused by hypervitaminosis D, but instead points to an underlying genetic cause that parallels the effect of Williams syndrome transcription factor deficiency in WBS. Furthermore, we observed normalization of serum calcium and vitamin D metabolite profiles at follow‐up of an IH patient where 25‐OH‐D was reduced to 9 ng/ml, suggesting that symptomatic IH may depend on vitamin D nutritional status. Other hypercalcemic patients with complex conditions exhibited distinct vitamin D metabolite profiles. Our work points to the importance of serum vitamin D metabolite profiling in the differential diagnosis of vitamin D–related hypercalcemia that can rationalize expensive genetic testing, and assist healthcare providers in selecting appropriate treatment. © 2021 American Society for Bone and Mineral Research (ASBMR).
doi_str_mv 10.1002/jbmr.4306
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03218618v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2513240951</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4886-2eee62cd65204d8ea8e6a9a1b4a5cdcd93ca6947d413aae3e39c5caf05708ce03</originalsourceid><addsrcrecordid>eNp10c1u1DAQB3ALgei2cOAFUCQu9JB2_LnOsR9AQYuQEJytWWfSeuUki50U7Y134A15EhK2tBISp5Gsn_6e0Z-xFxxOOIA43azbdKIkmEdswbWQpTKWP2YLsFaVoCQ_YIc5bwDAaGOesgMprTZLEAvWXIamoUTdEDAWdcDrrs8hF31T3IYB29AVl79-_EwUcaC6uNltKXmMntqAxZhDd11kSmP7oIuWBlz3MQxUbFPfhDihZ-xJgzHT87t5xL6-ffPl4qpcfXr3_uJsVXplrSkFERnha6MFqNoSWjJYIV8r1L72dSU9mkota8UlIkmSldceG9BLsJ5AHrHjfe4NRrdNocW0cz0Gd3W2cvMbSMGt4faWT_b13k5bfhspD64N2VOM2FE_Zic0l0JBpWf66h-66cfUTZdMSgsLlZH24XOf-pwTNfcbcHBzUW4uys1FTfblXeK4bqm-l3-bmcDpHnwPkXb_T3Ifzj9-_hP5G3-Knr4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2552809638</pqid></control><display><type>article</type><title>Differential diagnosis of vitamin D–related hypercalcemia using serum vitamin D metabolite profiling</title><source>Wiley Online Library Journals Frontfile Complete</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Kaufmann, Martin ; Schlingmann, Karl‐Peter ; Berezin, Linor ; Molin, Arnaud ; Sheftel, Jesse ; Vig, Melanie ; Gallagher, John C. ; Nagata, Akiko ; Masoud, Shadi Sedghi ; Sakamoto, Ryota ; Nagasawa, Kazuo ; Uesugi, Motonari ; Kottler, Marie Laure ; Konrad, Martin ; Jones, Glenville</creator><creatorcontrib>Kaufmann, Martin ; Schlingmann, Karl‐Peter ; Berezin, Linor ; Molin, Arnaud ; Sheftel, Jesse ; Vig, Melanie ; Gallagher, John C. ; Nagata, Akiko ; Masoud, Shadi Sedghi ; Sakamoto, Ryota ; Nagasawa, Kazuo ; Uesugi, Motonari ; Kottler, Marie Laure ; Konrad, Martin ; Jones, Glenville</creatorcontrib><description>ABSTRACT Genetic causes of vitamin D–related hypercalcemia are known to involve mutation of 25‐hydroxyvitamin D‐24‐hydroxylase CYP24A1 or the sodium phosphate co‐transporter SLC34A1, which result in excessive 1,25‐(OH)2D hormonal action. However, at least 20% of idiopathic hypercalcemia (IH) cases remain unresolved. In this case‐control study, we used precision vitamin D metabolite profiling based on liquid chromatography–tandem mass spectrometry (LC‐MS/MS) of an expanded range of vitamin D metabolites to screen German and French cohorts of hypercalcemia patients, to identify patients with altered vitamin D metabolism where involvement of CYP24A1 or SLC34A1 mutation had been ruled out and who possessed normal 25‐OH‐D3:24,25‐(OH)2D3 ratios. Profiles were compared to those of hypercalcemia patients with hypervitaminosis D, Williams‐Beuren syndrome (WBS), CYP24A1 mutation, and normal subjects with a range of 25‐OH‐D levels. We observed that certain IH and WBS patients exhibited a unique profile comprising eightfold to 10‐fold higher serum 23,25,26‐(OH)3D3 and 25‐OH‐D3‐26,23‐lactone than normals, as well as very low serum 1,25‐(OH)2D3 (2–5 pg/ml) and elevated 1,24,25‐(OH)3D3, which we interpret implies hypersensitive expression of vitamin D–dependent genes, including CYP24A1, as a general underlying mechanism of hypercalcemia in these patients. Because serum 25‐OH‐D3 and 24,25‐(OH)2D3 remained normal, we excluded the possibility that the aberrant profile was caused by hypervitaminosis D, but instead points to an underlying genetic cause that parallels the effect of Williams syndrome transcription factor deficiency in WBS. Furthermore, we observed normalization of serum calcium and vitamin D metabolite profiles at follow‐up of an IH patient where 25‐OH‐D was reduced to 9 ng/ml, suggesting that symptomatic IH may depend on vitamin D nutritional status. Other hypercalcemic patients with complex conditions exhibited distinct vitamin D metabolite profiles. Our work points to the importance of serum vitamin D metabolite profiling in the differential diagnosis of vitamin D–related hypercalcemia that can rationalize expensive genetic testing, and assist healthcare providers in selecting appropriate treatment. © 2021 American Society for Bone and Mineral Research (ASBMR).</description><identifier>ISSN: 0884-0431</identifier><identifier>EISSN: 1523-4681</identifier><identifier>DOI: 10.1002/jbmr.4306</identifier><identifier>PMID: 33856702</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>1,24,25‐TRIHYDROXYVITAMIN D3 ; 23,25,26‐TRIHYDROXYVITAMIN D3 ; 24,25‐DIHYDROXYVITAMIN D ; 25-Hydroxyvitamin D ; 25‐HYDROXYVITAMIN D3‐26,23‐LACTONE ; Calcium ; Calcium (blood) ; CELL/TISSUE SIGNALING–ENDOCRINE PATHWAYS ; CYP24A1 ; Differential diagnosis ; DISEASES AND DISORDERS OF/RELATED TO BONE ; Genetic screening ; Hydroxylase ; HYPERCALCEMIA ; Hypervitaminosis ; LC‐MS/MS ; Life Sciences ; Liquid chromatography ; Mass spectroscopy ; Metabolites ; Mutation ; NUTRITION ; Nutritional status ; Patients ; PTH/Vit D/FGF23 ; SCREENING ; Sodium phosphate ; Vitamin D ; Williams syndrome</subject><ispartof>Journal of bone and mineral research, 2021-07, Vol.36 (7), p.1340-1350</ispartof><rights>2021 American Society for Bone and Mineral Research (ASBMR).</rights><rights>2021 American Society for Bone and Mineral Research</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4886-2eee62cd65204d8ea8e6a9a1b4a5cdcd93ca6947d413aae3e39c5caf05708ce03</citedby><cites>FETCH-LOGICAL-c4886-2eee62cd65204d8ea8e6a9a1b4a5cdcd93ca6947d413aae3e39c5caf05708ce03</cites><orcidid>0000-0003-3192-9851 ; 0000-0001-7402-3473 ; 0000-0003-0163-2205 ; 0000-0003-0520-2800</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjbmr.4306$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjbmr.4306$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33856702$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://normandie-univ.hal.science/hal-03218618$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaufmann, Martin</creatorcontrib><creatorcontrib>Schlingmann, Karl‐Peter</creatorcontrib><creatorcontrib>Berezin, Linor</creatorcontrib><creatorcontrib>Molin, Arnaud</creatorcontrib><creatorcontrib>Sheftel, Jesse</creatorcontrib><creatorcontrib>Vig, Melanie</creatorcontrib><creatorcontrib>Gallagher, John C.</creatorcontrib><creatorcontrib>Nagata, Akiko</creatorcontrib><creatorcontrib>Masoud, Shadi Sedghi</creatorcontrib><creatorcontrib>Sakamoto, Ryota</creatorcontrib><creatorcontrib>Nagasawa, Kazuo</creatorcontrib><creatorcontrib>Uesugi, Motonari</creatorcontrib><creatorcontrib>Kottler, Marie Laure</creatorcontrib><creatorcontrib>Konrad, Martin</creatorcontrib><creatorcontrib>Jones, Glenville</creatorcontrib><title>Differential diagnosis of vitamin D–related hypercalcemia using serum vitamin D metabolite profiling</title><title>Journal of bone and mineral research</title><addtitle>J Bone Miner Res</addtitle><description>ABSTRACT Genetic causes of vitamin D–related hypercalcemia are known to involve mutation of 25‐hydroxyvitamin D‐24‐hydroxylase CYP24A1 or the sodium phosphate co‐transporter SLC34A1, which result in excessive 1,25‐(OH)2D hormonal action. However, at least 20% of idiopathic hypercalcemia (IH) cases remain unresolved. In this case‐control study, we used precision vitamin D metabolite profiling based on liquid chromatography–tandem mass spectrometry (LC‐MS/MS) of an expanded range of vitamin D metabolites to screen German and French cohorts of hypercalcemia patients, to identify patients with altered vitamin D metabolism where involvement of CYP24A1 or SLC34A1 mutation had been ruled out and who possessed normal 25‐OH‐D3:24,25‐(OH)2D3 ratios. Profiles were compared to those of hypercalcemia patients with hypervitaminosis D, Williams‐Beuren syndrome (WBS), CYP24A1 mutation, and normal subjects with a range of 25‐OH‐D levels. We observed that certain IH and WBS patients exhibited a unique profile comprising eightfold to 10‐fold higher serum 23,25,26‐(OH)3D3 and 25‐OH‐D3‐26,23‐lactone than normals, as well as very low serum 1,25‐(OH)2D3 (2–5 pg/ml) and elevated 1,24,25‐(OH)3D3, which we interpret implies hypersensitive expression of vitamin D–dependent genes, including CYP24A1, as a general underlying mechanism of hypercalcemia in these patients. Because serum 25‐OH‐D3 and 24,25‐(OH)2D3 remained normal, we excluded the possibility that the aberrant profile was caused by hypervitaminosis D, but instead points to an underlying genetic cause that parallels the effect of Williams syndrome transcription factor deficiency in WBS. Furthermore, we observed normalization of serum calcium and vitamin D metabolite profiles at follow‐up of an IH patient where 25‐OH‐D was reduced to 9 ng/ml, suggesting that symptomatic IH may depend on vitamin D nutritional status. Other hypercalcemic patients with complex conditions exhibited distinct vitamin D metabolite profiles. Our work points to the importance of serum vitamin D metabolite profiling in the differential diagnosis of vitamin D–related hypercalcemia that can rationalize expensive genetic testing, and assist healthcare providers in selecting appropriate treatment. © 2021 American Society for Bone and Mineral Research (ASBMR).</description><subject>1,24,25‐TRIHYDROXYVITAMIN D3</subject><subject>23,25,26‐TRIHYDROXYVITAMIN D3</subject><subject>24,25‐DIHYDROXYVITAMIN D</subject><subject>25-Hydroxyvitamin D</subject><subject>25‐HYDROXYVITAMIN D3‐26,23‐LACTONE</subject><subject>Calcium</subject><subject>Calcium (blood)</subject><subject>CELL/TISSUE SIGNALING–ENDOCRINE PATHWAYS</subject><subject>CYP24A1</subject><subject>Differential diagnosis</subject><subject>DISEASES AND DISORDERS OF/RELATED TO BONE</subject><subject>Genetic screening</subject><subject>Hydroxylase</subject><subject>HYPERCALCEMIA</subject><subject>Hypervitaminosis</subject><subject>LC‐MS/MS</subject><subject>Life Sciences</subject><subject>Liquid chromatography</subject><subject>Mass spectroscopy</subject><subject>Metabolites</subject><subject>Mutation</subject><subject>NUTRITION</subject><subject>Nutritional status</subject><subject>Patients</subject><subject>PTH/Vit D/FGF23</subject><subject>SCREENING</subject><subject>Sodium phosphate</subject><subject>Vitamin D</subject><subject>Williams syndrome</subject><issn>0884-0431</issn><issn>1523-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp10c1u1DAQB3ALgei2cOAFUCQu9JB2_LnOsR9AQYuQEJytWWfSeuUki50U7Y134A15EhK2tBISp5Gsn_6e0Z-xFxxOOIA43azbdKIkmEdswbWQpTKWP2YLsFaVoCQ_YIc5bwDAaGOesgMprTZLEAvWXIamoUTdEDAWdcDrrs8hF31T3IYB29AVl79-_EwUcaC6uNltKXmMntqAxZhDd11kSmP7oIuWBlz3MQxUbFPfhDihZ-xJgzHT87t5xL6-ffPl4qpcfXr3_uJsVXplrSkFERnha6MFqNoSWjJYIV8r1L72dSU9mkota8UlIkmSldceG9BLsJ5AHrHjfe4NRrdNocW0cz0Gd3W2cvMbSMGt4faWT_b13k5bfhspD64N2VOM2FE_Zic0l0JBpWf66h-66cfUTZdMSgsLlZH24XOf-pwTNfcbcHBzUW4uys1FTfblXeK4bqm-l3-bmcDpHnwPkXb_T3Ifzj9-_hP5G3-Knr4</recordid><startdate>202107</startdate><enddate>202107</enddate><creator>Kaufmann, Martin</creator><creator>Schlingmann, Karl‐Peter</creator><creator>Berezin, Linor</creator><creator>Molin, Arnaud</creator><creator>Sheftel, Jesse</creator><creator>Vig, Melanie</creator><creator>Gallagher, John C.</creator><creator>Nagata, Akiko</creator><creator>Masoud, Shadi Sedghi</creator><creator>Sakamoto, Ryota</creator><creator>Nagasawa, Kazuo</creator><creator>Uesugi, Motonari</creator><creator>Kottler, Marie Laure</creator><creator>Konrad, Martin</creator><creator>Jones, Glenville</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><general>American Society for Bone and Mineral Research</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TS</scope><scope>K9.</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-3192-9851</orcidid><orcidid>https://orcid.org/0000-0001-7402-3473</orcidid><orcidid>https://orcid.org/0000-0003-0163-2205</orcidid><orcidid>https://orcid.org/0000-0003-0520-2800</orcidid></search><sort><creationdate>202107</creationdate><title>Differential diagnosis of vitamin D–related hypercalcemia using serum vitamin D metabolite profiling</title><author>Kaufmann, Martin ; Schlingmann, Karl‐Peter ; Berezin, Linor ; Molin, Arnaud ; Sheftel, Jesse ; Vig, Melanie ; Gallagher, John C. ; Nagata, Akiko ; Masoud, Shadi Sedghi ; Sakamoto, Ryota ; Nagasawa, Kazuo ; Uesugi, Motonari ; Kottler, Marie Laure ; Konrad, Martin ; Jones, Glenville</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4886-2eee62cd65204d8ea8e6a9a1b4a5cdcd93ca6947d413aae3e39c5caf05708ce03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>1,24,25‐TRIHYDROXYVITAMIN D3</topic><topic>23,25,26‐TRIHYDROXYVITAMIN D3</topic><topic>24,25‐DIHYDROXYVITAMIN D</topic><topic>25-Hydroxyvitamin D</topic><topic>25‐HYDROXYVITAMIN D3‐26,23‐LACTONE</topic><topic>Calcium</topic><topic>Calcium (blood)</topic><topic>CELL/TISSUE SIGNALING–ENDOCRINE PATHWAYS</topic><topic>CYP24A1</topic><topic>Differential diagnosis</topic><topic>DISEASES AND DISORDERS OF/RELATED TO BONE</topic><topic>Genetic screening</topic><topic>Hydroxylase</topic><topic>HYPERCALCEMIA</topic><topic>Hypervitaminosis</topic><topic>LC‐MS/MS</topic><topic>Life Sciences</topic><topic>Liquid chromatography</topic><topic>Mass spectroscopy</topic><topic>Metabolites</topic><topic>Mutation</topic><topic>NUTRITION</topic><topic>Nutritional status</topic><topic>Patients</topic><topic>PTH/Vit D/FGF23</topic><topic>SCREENING</topic><topic>Sodium phosphate</topic><topic>Vitamin D</topic><topic>Williams syndrome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaufmann, Martin</creatorcontrib><creatorcontrib>Schlingmann, Karl‐Peter</creatorcontrib><creatorcontrib>Berezin, Linor</creatorcontrib><creatorcontrib>Molin, Arnaud</creatorcontrib><creatorcontrib>Sheftel, Jesse</creatorcontrib><creatorcontrib>Vig, Melanie</creatorcontrib><creatorcontrib>Gallagher, John C.</creatorcontrib><creatorcontrib>Nagata, Akiko</creatorcontrib><creatorcontrib>Masoud, Shadi Sedghi</creatorcontrib><creatorcontrib>Sakamoto, Ryota</creatorcontrib><creatorcontrib>Nagasawa, Kazuo</creatorcontrib><creatorcontrib>Uesugi, Motonari</creatorcontrib><creatorcontrib>Kottler, Marie Laure</creatorcontrib><creatorcontrib>Konrad, Martin</creatorcontrib><creatorcontrib>Jones, Glenville</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Physical Education Index</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Journal of bone and mineral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaufmann, Martin</au><au>Schlingmann, Karl‐Peter</au><au>Berezin, Linor</au><au>Molin, Arnaud</au><au>Sheftel, Jesse</au><au>Vig, Melanie</au><au>Gallagher, John C.</au><au>Nagata, Akiko</au><au>Masoud, Shadi Sedghi</au><au>Sakamoto, Ryota</au><au>Nagasawa, Kazuo</au><au>Uesugi, Motonari</au><au>Kottler, Marie Laure</au><au>Konrad, Martin</au><au>Jones, Glenville</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential diagnosis of vitamin D–related hypercalcemia using serum vitamin D metabolite profiling</atitle><jtitle>Journal of bone and mineral research</jtitle><addtitle>J Bone Miner Res</addtitle><date>2021-07</date><risdate>2021</risdate><volume>36</volume><issue>7</issue><spage>1340</spage><epage>1350</epage><pages>1340-1350</pages><issn>0884-0431</issn><eissn>1523-4681</eissn><abstract>ABSTRACT Genetic causes of vitamin D–related hypercalcemia are known to involve mutation of 25‐hydroxyvitamin D‐24‐hydroxylase CYP24A1 or the sodium phosphate co‐transporter SLC34A1, which result in excessive 1,25‐(OH)2D hormonal action. However, at least 20% of idiopathic hypercalcemia (IH) cases remain unresolved. In this case‐control study, we used precision vitamin D metabolite profiling based on liquid chromatography–tandem mass spectrometry (LC‐MS/MS) of an expanded range of vitamin D metabolites to screen German and French cohorts of hypercalcemia patients, to identify patients with altered vitamin D metabolism where involvement of CYP24A1 or SLC34A1 mutation had been ruled out and who possessed normal 25‐OH‐D3:24,25‐(OH)2D3 ratios. Profiles were compared to those of hypercalcemia patients with hypervitaminosis D, Williams‐Beuren syndrome (WBS), CYP24A1 mutation, and normal subjects with a range of 25‐OH‐D levels. We observed that certain IH and WBS patients exhibited a unique profile comprising eightfold to 10‐fold higher serum 23,25,26‐(OH)3D3 and 25‐OH‐D3‐26,23‐lactone than normals, as well as very low serum 1,25‐(OH)2D3 (2–5 pg/ml) and elevated 1,24,25‐(OH)3D3, which we interpret implies hypersensitive expression of vitamin D–dependent genes, including CYP24A1, as a general underlying mechanism of hypercalcemia in these patients. Because serum 25‐OH‐D3 and 24,25‐(OH)2D3 remained normal, we excluded the possibility that the aberrant profile was caused by hypervitaminosis D, but instead points to an underlying genetic cause that parallels the effect of Williams syndrome transcription factor deficiency in WBS. Furthermore, we observed normalization of serum calcium and vitamin D metabolite profiles at follow‐up of an IH patient where 25‐OH‐D was reduced to 9 ng/ml, suggesting that symptomatic IH may depend on vitamin D nutritional status. Other hypercalcemic patients with complex conditions exhibited distinct vitamin D metabolite profiles. Our work points to the importance of serum vitamin D metabolite profiling in the differential diagnosis of vitamin D–related hypercalcemia that can rationalize expensive genetic testing, and assist healthcare providers in selecting appropriate treatment. © 2021 American Society for Bone and Mineral Research (ASBMR).</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>33856702</pmid><doi>10.1002/jbmr.4306</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-3192-9851</orcidid><orcidid>https://orcid.org/0000-0001-7402-3473</orcidid><orcidid>https://orcid.org/0000-0003-0163-2205</orcidid><orcidid>https://orcid.org/0000-0003-0520-2800</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0884-0431
ispartof Journal of bone and mineral research, 2021-07, Vol.36 (7), p.1340-1350
issn 0884-0431
1523-4681
language eng
recordid cdi_hal_primary_oai_HAL_hal_03218618v1
source Wiley Online Library Journals Frontfile Complete; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals
subjects 1,24,25‐TRIHYDROXYVITAMIN D3
23,25,26‐TRIHYDROXYVITAMIN D3
24,25‐DIHYDROXYVITAMIN D
25-Hydroxyvitamin D
25‐HYDROXYVITAMIN D3‐26,23‐LACTONE
Calcium
Calcium (blood)
CELL/TISSUE SIGNALING–ENDOCRINE PATHWAYS
CYP24A1
Differential diagnosis
DISEASES AND DISORDERS OF/RELATED TO BONE
Genetic screening
Hydroxylase
HYPERCALCEMIA
Hypervitaminosis
LC‐MS/MS
Life Sciences
Liquid chromatography
Mass spectroscopy
Metabolites
Mutation
NUTRITION
Nutritional status
Patients
PTH/Vit D/FGF23
SCREENING
Sodium phosphate
Vitamin D
Williams syndrome
title Differential diagnosis of vitamin D–related hypercalcemia using serum vitamin D metabolite profiling
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T13%3A16%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20diagnosis%20of%20vitamin%20D%E2%80%93related%20hypercalcemia%20using%20serum%20vitamin%20D%20metabolite%20profiling&rft.jtitle=Journal%20of%20bone%20and%20mineral%20research&rft.au=Kaufmann,%20Martin&rft.date=2021-07&rft.volume=36&rft.issue=7&rft.spage=1340&rft.epage=1350&rft.pages=1340-1350&rft.issn=0884-0431&rft.eissn=1523-4681&rft_id=info:doi/10.1002/jbmr.4306&rft_dat=%3Cproquest_hal_p%3E2513240951%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2552809638&rft_id=info:pmid/33856702&rfr_iscdi=true